Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-055065
Filing Date
2021-11-08
Accepted
2021-11-08 08:00:43
Documents
69
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q vcnx-10q_20210930.htm   iXBRL 10-Q 2073171
2 EX-31.1 vcnx-ex311_14.htm EX-31.1 21938
3 EX-31.2 vcnx-ex312_12.htm EX-31.2 22614
4 EX-32.1 vcnx-ex321_13.htm EX-32.1 10859
  Complete submission text file 0001564590-21-055065.txt   6857607

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA vcnx-20210930.xsd EX-101.SCH 51616
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vcnx-20210930_cal.xml EX-101.CAL 35768
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vcnx-20210930_def.xml EX-101.DEF 177233
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE vcnx-20210930_lab.xml EX-101.LAB 390549
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vcnx-20210930_pre.xml EX-101.PRE 307374
10 EXTRACTED XBRL INSTANCE DOCUMENT vcnx-10q_20210930_htm.xml XML 1037822
Mailing Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620
Business Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620 585-271-2700
VACCINEX, INC. (Filer) CIK: 0001205922 (see all company filings)

EIN.: 161603202 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38624 | Film No.: 211386562
SIC: 2834 Pharmaceutical Preparations